Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Cancer Therapies02:49

Cancer Therapies

9.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Cancer Vaccines01:30

Cancer Vaccines

878
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
878

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and Efficacy of Atezolizumab in Combination With nab-Paclitaxel in Patients With PD-L1 Positive Metastatic or Locally Advanced Triple-Negative Breast Cancer: A UK-Wide Cancer Centre Experience.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025
Same author

Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials.

European journal of cancer (Oxford, England : 1990)·2018
Same author

Comparison of published and unpublished phase I clinical cancer trials: an analysis of the CliniclTrials.gov database.

Investigational new drugs·2017
Same author

Comparison of reporting phase I trial results in ClinicalTrials.gov and matched publications.

Investigational new drugs·2017
Same author

A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors.

Investigational new drugs·2016
Same author

The prevalence of metabolic syndrome in persons with type 2 diabetes at the Lagos University Tteaching Hospital, Lagos, Nigeria.

West African journal of medicine·2013

Related Experiment Video

Updated: Dec 26, 2025

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.1K

Immunotherapy in soft-tissue sarcoma.

O Ayodele1, A R Abdul Razak1

  • 1Toronto Sarcoma Program, Princess Margaret Cancer Centre and Mount Sinai Hospital, Toronto, ON.

Current Oncology (Toronto, Ont.)
|March 17, 2020
PubMed
Summary
This summary is machine-generated.

Soft-tissue sarcoma (STS) is a rare cancer. Immunotherapies, including immune checkpoint inhibitors and cancer vaccines, show promise for advanced STS, offering new hope for patients with limited systemic therapy options.

Keywords:
Adoptive cell therapyalveolar soft-part sarcomacancer vaccinescheckpoint inhibitorsimmunotherapysoft-tissue sarcomaundifferentiated pleomorphic sarcoma

More Related Videos

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

13.1K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.8K

Related Experiment Videos

Last Updated: Dec 26, 2025

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.1K
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

13.1K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.8K

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Soft-tissue sarcoma (STS) is a rare mesenchymal malignancy, comprising <1% of adult tumors.
  • Localized therapies (surgery, radiotherapy) are effective but STS often recurs with metastatic disease.
  • Systemic therapies for advanced STS have modest efficacy and poor survival rates.

Purpose of the Study:

  • To review current data and ongoing clinical trials of immunotherapies in patients with STS.
  • To explore the potential of immunotherapy for STS based on tumor biology.
  • To highlight novel treatment strategies for advanced STS.

Main Methods:

  • Targeted review of published literature on STS immunotherapies.
  • Analysis of ongoing clinical trials involving immune checkpoint inhibitors, adoptive cell therapies, and cancer vaccines.
  • Examination of STS biology relevant to immunotherapy, including cancer/testis antigens.

Main Results:

  • Interest in immunotherapy for STS is growing, spurred by successes in other cancers.
  • Certain STS subtypes possess biological features amenable to immunotherapy interventions.
  • Clinical trials are actively investigating various immunotherapy approaches for STS patients.

Conclusions:

  • Immunotherapy represents a promising frontier for advanced soft-tissue sarcoma treatment.
  • Further research and clinical trials are crucial to realize the full potential of immunotherapies in STS.
  • Novel approaches like immune checkpoint inhibitors and cancer vaccines offer new hope for improved outcomes.